{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:17:51Z","timestamp":1792275471528,"version":"4.4.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ncl.2018.01.008","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T18:14:39Z","timestamp":1523470479000},"page":"379-394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Lambert-Eaton Myasthenic Syndrome"],"prefix":"10.1016","volume":"36","author":[{"given":"Vita G.","family":"Kesner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin J.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ncl.2018.01.008_bib1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(53)91358-0","article-title":"Bronchial neoplasm with myasthenia: prolonged apnea after administration of succinylcholine","volume":"265","author":"Anderson","year":"1953","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2018.01.008_bib2","first-page":"612","article-title":"Defect of neuromuscular conduction associated with malignant neoplasms","volume":"187","author":"Lambert","year":"1956","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ncl.2018.01.008_bib3","first-page":"1117","article-title":"Electromyography and electrical stimulation of nerves in diseases of the motor unit: observations on a myasthenic syndrome associated with malignant tumours","volume":"163","author":"Eaton","year":"1957","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ncl.2018.01.008_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0025-7125(16)33984-0","article-title":"Myasthenia and malignant intrathoracic tumor","volume":"44","author":"Rooke","year":"1960","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.ncl.2018.01.008_bib5","series-title":"The remote effect of cancer on the nervous system","first-page":"67","article-title":"Myasthenic state and lung cancer","author":"Lambert","year":"1965"},{"key":"10.1016\/j.ncl.2018.01.008_bib6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/mus.880050905","article-title":"Paucity and disorganization of presynaptic membrane active zones in the Lambert\u2013Eaton myasthenic syndrome","volume":"5","author":"Fukunaga","year":"1982","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib7","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","article-title":"Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes","volume":"332","author":"Lennon","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.008_bib8","first-page":"698","article-title":"Dutch Myasthenia Study Group. The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland","volume":"250","author":"Wirtz","year":"2003","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2018.01.008_bib9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1196\/annals.1254.065","article-title":"Lambert-Eaton myasthenic syndrome: diagnosis and treatment","volume":"998","author":"Sanders","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ncl.2018.01.008_bib10","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","article-title":"Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS","volume":"29","author":"Titulaer","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ncl.2018.01.008_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0303-8467(02)00054-9","article-title":"Differences in clinical features between the Lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases","volume":"104","author":"Wirtz","year":"2002","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.ncl.2018.01.008_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jneuroim.2004.10.018","article-title":"HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert-Eaton myasthenic syndrome","volume":"159","author":"Wirtz","year":"2005","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.ncl.2018.01.008_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1196\/annals.1405.030","article-title":"Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms","volume":"1132","author":"Titulaer","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ncl.2018.01.008_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","article-title":"The Lambert-Eaton myasthenic syndrome: a review of 50 cases","volume":"111","author":"O\u2019Neill","year":"1988","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2018.01.008_bib15","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.410400510","article-title":"Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma","volume":"40","author":"Meriney","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2018.01.008_bib16","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0025-6196(12)61144-6","article-title":"Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma","volume":"67","author":"Oguro-Okano","year":"1992","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.008_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/mus.25027","article-title":"P\/Q- and N-type calcium-channel antibodies: oncological, neurological, and serological accompaniments","volume":"54","author":"Zalewski","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib18","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1113\/jphysiol.1996.sp021800","article-title":"Calcium channels involved in synaptic transmission at the mature and regenerating mouse neuromuscular junction","volume":"497","author":"Katz","year":"1996","journal-title":"J\u00a0Physiol"},{"key":"10.1016\/j.ncl.2018.01.008_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1126\/science.2447647","article-title":"Dominant role of N-type Ca21 channels in evoked release of norepinephrine from sympathetic neurons","volume":"239","author":"Hirning","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ncl.2018.01.008_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0140-6736(81)90474-8","article-title":"Autoimmune etiology for myasthenic (Eaton-Lambert) syndrome","volume":"2","author":"Lang","year":"1981","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ncl.2018.01.008_bib21","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2018.01.008_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jneuroim.2008.05.025","article-title":"The Lambert-Eaton myasthenic syndrome 1988\u20132008: a clinical picture in 97 patients","volume":"201\u201302","author":"Titulaer","year":"2008","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.ncl.2018.01.008_bib23","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/ana.10477","article-title":"Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome","volume":"53","author":"Burns","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2018.01.008_bib24","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/WNO.0000000000000258","article-title":"Lambert Eaton myasthenic syndrome: ocular signs and symptoms","volume":"36","author":"Young","year":"2016","journal-title":"J\u00a0Neuroophthalmol"},{"key":"10.1016\/j.ncl.2018.01.008_bib25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/archneur.1974.00490390065006","article-title":"The Eaton-Lambert syndrome in ocular myasthenia gravis","volume":"31","author":"Oh","year":"1974","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ncl.2018.01.008_bib26","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000264798.56174.df","article-title":"Lambert-Eaton myasthenic syndrome with pure ocular weakness","volume":"68","author":"Rudnicki","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1212\/WNL.46.4.1143","article-title":"Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine","volume":"46","author":"Smith","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib28","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1590\/S0004-282X2010000600004","article-title":"Non-paraneoplastic Lambert-Eaton myasthenic syndrome: a brief review of 10 cases","volume":"68","author":"Lorenzoni","year":"2010","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.ncl.2018.01.008_bib29","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2009.09.017","article-title":"Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients","volume":"217","author":"Pellkofer","year":"2009","journal-title":"J\u00a0Neuroimmunol"},{"key":"10.1016\/j.ncl.2018.01.008_bib30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.410420204","article-title":"Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse","volume":"42","author":"Waterman","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2018.01.008_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-510X(88)90037-8","article-title":"Autonomic dysfunction in Lambert-Eaton myasthenic syndrome","volume":"85","author":"Khurana","year":"1988","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2018.01.008_bib32","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","article-title":"Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome","volume":"32","author":"Oh","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib33","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1212\/WNL.59.7.1085","article-title":"Postexercise facilitation of re\ufb02exes is not common in Lambert-Eaton myasthenic syndrome","volume":"59","author":"Odabasi","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/mus.24921","article-title":"Myasthenia gravis Lambert-Eaton overlap syndrome","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","article-title":"Incidence of serum anti-P\/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"147","author":"Motomura","year":"1997","journal-title":"J\u00a0Neurol Sci"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.008_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/mus.24295","article-title":"Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels","volume":"51","author":"Hajela","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib37","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","article-title":"Seronegative Lambert-Eaton myasthenic syndrome","volume":"59","author":"Nakao","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/mus.20672","article-title":"Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome","volume":"35","author":"Oh","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1212\/01.wnl.0000281663.81079.24","article-title":"SOX1 antibodies are markers of paraneoplastic Lambert\u2013Eaton myasthenic syndrome","volume":"70","author":"Sabater","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib40","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.2008.20.6169","article-title":"SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival","volume":"27","author":"Titulaer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ncl.2018.01.008_bib41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/mus.880120605","article-title":"Diverse electrophysiological spectrum of the Lambert-Eaton myasthenic syndrome","volume":"12","author":"Oh","year":"1989","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib42","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1749-6632.1998.tb11024.x","article-title":"Lambert-Eaton myasthenic syndrome (LEMS): clinical and electrodiagnostic features and response to therapy in 59 patients","volume":"841","author":"Tim","year":"1998","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.008_bib43","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.clinph.2013.11.007","article-title":"Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis?","volume":"125","author":"Sanders","year":"2014","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.ncl.2018.01.008_bib44","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/mus.20979","article-title":"Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome","volume":"37","author":"Hatanaka","year":"2008","journal-title":"Muscle Nerve"},{"issue":"9","key":"10.1016\/j.ncl.2018.01.008_bib45","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/mus.880170906","article-title":"Repetitive nerve stimulation studies in the Lambert-Eaton myasthenic syndrome","volume":"17","author":"Tim","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib46","series-title":"Electromyography: neuromuscular transmission studies","author":"Oh","year":"1988"},{"key":"10.1016\/j.ncl.2018.01.008_bib47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp.65.2.213","article-title":"Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome","volume":"65","author":"Maddison","year":"1998","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2018.01.008_bib48","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/(SICI)1097-4598(199609)19:9<1069::AID-MUS1>3.0.CO;2-Y","article-title":"AAEM minimonograph #25: single-fiber electromyography","volume":"19","author":"Sanders","year":"1996","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.008_bib49","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/mus.23638","article-title":"Single-fiber EMG and clinical correlation in Lambert-Eaton myasthenic syndrome","volume":"47","author":"Oh","year":"2013","journal-title":"Muscle Nerve"},{"issue":"12","key":"10.1016\/j.ncl.2018.01.008_bib50","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/mus.880141215","article-title":"Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome","volume":"14","author":"Chaudhry","year":"1991","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib51","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1200\/JCO.2008.17.5133","article-title":"Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome","volume":"26","author":"Titulaer","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ncl.2018.01.008_bib52","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1212\/WNL.54.11.2176","article-title":"Lambert-Eaton myasthenic syndrome: electrodiagnostic \ufb01nding and response to treatment","volume":"54","author":"Tim","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib53","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/(SICI)1097-4598(199709)20:9<1146::AID-MUS9>3.0.CO;2-8","article-title":"Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome","volume":"20","author":"Oh","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib54","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0014-2999(80)90378-7","article-title":"Potency of 3,4-diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes","volume":"61","author":"Molgo","year":"1980","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ncl.2018.01.008_bib55","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJM198912073212303","article-title":"3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome","volume":"321","author":"McEvoy","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ncl.2018.01.008_bib56","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","article-title":"3,4-Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS","volume":"40","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.ncl.2018.01.008_bib57","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","article-title":"A\u00a0randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome","volume":"54","author":"Sanders","year":"2000","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ncl.2018.01.008_bib58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","article-title":"Ef\ufb01cacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study","volume":"86","author":"Wirtz","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.008_bib59","article-title":"Treatment for Lambert-Eaton myasthenic syndrome","author":"Keogh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ncl.2018.01.008_bib60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jpba.2006.06.007","article-title":"Stability studies of ionised and non-ionised 3,4-diaminopyridine: hypothesis of degradation pathways and chemical structure of degradation products","volume":"43","author":"Raust","year":"2007","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"5","key":"10.1016\/j.ncl.2018.01.008_bib61","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/mus.25070","article-title":"Amifampridine phosphate (Firdapse(\u00ae)) is effective and safe in a phase 3 clinical trial in LEMS","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib62","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.ncl.2018.01.008_bib63","first-page":"I14","article-title":"IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status","volume":"252","author":"Illa","year":"2005","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.008_bib64","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.0.CO;2-5","article-title":"Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin","volume":"20","author":"Muchnik","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2018.01.008_bib65","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.42.7.1422","article-title":"Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy","volume":"42","author":"Bird","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib66","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","article-title":"Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome","volume":"34","author":"Newsom-Davis","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib67","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1749-6632.1998.tb11023.x","article-title":"A\u00a0treatment algorithm for Lambert-Eaton myasthenic syndrome","volume":"841","author":"Newsom-Davis","year":"1998","journal-title":"Ann NY Acad Sci"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.008_bib68","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jnnp.70.2.212","article-title":"Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer","volume":"70","author":"Maddison","year":"2001","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.ncl.2018.01.008_bib69","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1749-6632.2012.06769.x","article-title":"Treatment in Lambert-Eaton myasthenic syndrome","volume":"1275","author":"Maddison","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"10.1016\/j.ncl.2018.01.008_bib70","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2018.01.008_bib71","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/mus.21315","article-title":"Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction","volume":"40","author":"Pellkofer","year":"2009","journal-title":"Muscle Nerve"},{"issue":"8","key":"10.1016\/j.ncl.2018.01.008_bib72","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.revmed.2013.04.007","article-title":"Favourable outcome after treatment with rituximab in a case of seronegative non-paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"34","author":"Boutin","year":"2013","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.ncl.2018.01.008_bib73","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.40.10.1552","article-title":"Responses of the Lambert-Eason myasthenic syndrome to treatment of associated small-cell lung cancer","volume":"40","author":"Chalk","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.01.008_bib74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(05)76153-5","article-title":"Favorable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma","volume":"353","author":"Maddisson","year":"1999","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.ncl.2018.01.008_bib75","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1212\/WNL.0000000000003794","article-title":"Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome","volume":"88","author":"Maddison","year":"2017","journal-title":"Neurology"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918300082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918300082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T10:29:55Z","timestamp":1534933795000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861918300082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0733861918300082"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2018.01.008","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lambert-Eaton Myasthenic Syndrome","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2018.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}